Clin Microbiol Infect. 2020 Jul 13:S1198-743X(20)30388-8. doi: 10.1016/j.cmi.2020.07.005. Online ahead of print.
OBJECTIVES: Vancomycin dose recommendations depend on population pharmacokinetic models. These models have not been adequately assessed in critically ill patients, whom exhibit large pharmacokinetic variability. This study evaluated model predictive performance in Intensive Care Unit (ICU) patients and identified factors influencing model performance.
METHODS: Retrospective data from ICU adult patients administered vancomycin were used to evaluate model performance to predict serum concentrations a priori (no observed concentrations included) or with Bayesian forecasting (using concentration data). Predictive performance was determined using relative bias (rBias, bias) and relative root mean squared error (rRMSE, precision). Models were considered clinically acceptable if rBias was between ±20%, and 95% confidence intervals included zero. Models were compared with rRMSE, no threshold was employed. The influence of clinical factors on model performance was assessed with multiple linear regression.
RESULTS: Data from 82 patients were used to evaluate 12 vancomycin models. The Goti model was the only clinically acceptable model with both a priori (rBias 3.4%) and Bayesian forecasting (rBias 1.5%) approaches. Bayesian forecasting was superior to a priori prediction, improving with the use of more recent concentrations. Four models were clinically acceptable with Bayesian forecasting. Renal replacement therapy status (p<0.001) and sex (p<0.007) significantly influenced the performance of the Goti model.
CONCLUSIONS: The Goti, Llopis and Roberts models are clinically appropriate to inform vancomycin dosing in critically ill patients. Implementing the Goti model in dose prediction software could streamline dosing across both ICU and non-ICU patients considering it is also the most accurate model in non-ICU patients.